Enoxaparin and bleeding complications: A review in patients with and without renal insufficiency

Pharmacotherapy

Volumn 20, Issue 7 I, 2000, Pages 771-775

  Gerlach, Anthony T ^a,d   Pickworth, Kerry K ^a   Seth, Shiv K ^a   Tanna, Saloni B ^b   Barnes, Julie F ^c  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b BOSTON MEDICAL CENTER   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CREATININE CLEARANCE; DOSE CALCULATION; DRUG SAFETY; FEMALE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE;

EID: 0033923679     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.20.9.771.35210     Document Type: Article

References (12)

1. Rhône-Poulenc Rorer Pharmaceuticals. Lovenox (enoxaparin) package insert. Collegeville, PA; December 1998.
2. Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety. Chest 1998;114:489S-510.
3. Abbate R, Gori AM, Farsi A, Attanasio M, Pepe G. Monitoring of low-molecular-weight heparins in cardiovascular disease. Am J Cardiol 1998;82:33L-6.
4. Fareed J, Jeske W, Hoppensteadt D, Clarizio R, Walengo JM. Low-molecular-weight heparins: pharmacologic profile and product differentiation. Am J Cardiol 1998;82:3L-10.
5. Yee WP, Norton LL. Optimal weight base for a weight-based heparin dosing protocol. Am J Health-Syst Pharm 1998;55;159-62.
6. Rodgers GM. Inappropriate use of enoxaparin in the treatment of deep-vein thrombosis [letter]. N Engl J Med 1999;340:62.
7. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447-52.
8. Bergqvist D, Benoni G, Bjorell O, et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996;335:696-700.
9. Cadroy Y, Pourrat J, Baladre MF, et al. Delayed elimination of enoxaparin in patients with chronic renal insufficiency. Thromb Res 1991;63:385-90.
10. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11b trial. Circulation 1999;100:1593-601.
11. Geerts WH, Jay RM, Code KI, et al. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med 1996;335:701-7.
12. Brady HR, Brenner BM. Acute renal failure. In: Isselbacher KJ, Braunwald E, Wilson JD, et al, eds. Harrison's principles of internal medicine, 13th ed. New York: McGraw-Hill, 1994:1265-74.